Cocrystal Pharma, Inc. (OTCBB:COCP) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain OfficersItem 5.02
Cocrystal Pharma, Inc. (OTCBB:COCP) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers; Compensatory Arrangements of Certain Officers
On February 12, 2017, Walt A. Linscott informed the Board of Directors of Cocrystal Pharma, Inc. (the “Company”) of his resignation as General Counsel and Secretary of the Company, effective March 1, 2017. Mr. Linscott has accepted a position as President, Chief Operating Officer and General Counsel of a start-up biotechnology company.
About Cocrystal Pharma, Inc. (OTCBB:COCP)
Cocrystal Pharma, Inc., formerly Biozone Pharmaceuticals, Inc., is engaged in developing medicines for use in the treatment of human viral diseases. The Company develops technologies and approaches to create antiviral drug candidates. The Company is developing antiviral therapeutics that inhibit the replication function of a virus, including the ribonucleic acid (RNA)-dependent RNA polymerase enzyme, the helicase enzyme and the NS5A protein of hepatitis C virus (HCV), and the polymerase enzymes of influenza virus and norovirus. The polymerase inhibitors include both nucleosides (Nucs) and non-nucleosides. Its platform consists of computation, medicinal chemistry, click chemistry and X-ray crystallography. The Company determines the structures of cocrystals containing the inhibitors bound to the enzyme or protein to guide its design. The Company uses computational methods to screen and design product candidates using its cocrystal structural information. Cocrystal Pharma, Inc. (OTCBB:COCP) Recent Trading Information
Cocrystal Pharma, Inc. (OTCBB:COCP) closed its last trading session up +0.015 at 0.320 with 389,157 shares trading hands.
Cocrystal Pharma, Inc., formerly Biozone Pharmaceuticals, Inc., is engaged in developing medicines for use in the treatment of human viral diseases. The Company develops technologies and approaches to create antiviral drug candidates. The Company is developing antiviral therapeutics that inhibit the replication function of a virus, including the ribonucleic acid (RNA)-dependent RNA polymerase enzyme, the helicase enzyme and the NS5A protein of hepatitis C virus (HCV), and the polymerase enzymes of influenza virus and norovirus. The polymerase inhibitors include both nucleosides (Nucs) and non-nucleosides. Its platform consists of computation, medicinal chemistry, click chemistry and X-ray crystallography. The Company determines the structures of cocrystals containing the inhibitors bound to the enzyme or protein to guide its design. The Company uses computational methods to screen and design product candidates using its cocrystal structural information. Cocrystal Pharma, Inc. (OTCBB:COCP) Recent Trading Information
Cocrystal Pharma, Inc. (OTCBB:COCP) closed its last trading session up +0.015 at 0.320 with 389,157 shares trading hands.
